Our analysis showed that higher JAG2 expression levels were associated with a poorer clinical outcome in terms of both overall survival (OS) and progression-free survival (PFS), as depicted in Figure 3A. Conversely, while the JAG1 expression level displayed a positive correlation with MM disease progression [13], it did not impact the clinical outcomes of MM patients (Supplementary Figure S1). Here, JAG1 is linked to Miyoshi myopathy.